# HanchorBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hanchorbio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $10M
- Latest round: Series A (Sep 8, 2022)
- Investors on record: 5

## About

Based in Shanghai, China, and established in 2020, HanchorBio is a biopharmaceutical company that focuses on R&D anti-tumor drugs. It has additional offices in Taipei, Shanghai, and San Francisco. As of September 2022, Hanchor Bio raised two rounds of funding. 

HanchorBio provides biological drug FBDBs, based on the molecular design of peptide-Fc, which can activate the immune system against tumors.

HanchorBio will use the series A funding to accelerate the R&D process of the biological drug FBDB, including pre-clinical, new drug filing, and the first phase clinical trial.

## Funding rounds

- Series A, Sep 8, 2022, $10M — Sino Biopharmaceutical Limited, Yuexiu Industrial Investment Funds Management, Zero2IPO, YuanBio Venture, Panacea Venture
- Angel, Apr 1, 2021 — YuanBio Venture

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel, Series A
- Sino Biopharmaceutical Limited — Series A
- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Series A
- Zero2IPO — Series A
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series A